Anteris Technologies Global Corp. heads into its November earnings date with a notable split between institutional conviction and persistent stock-level weakness — the past month has erased nearly 10% of the share price even as some of the largest holders quietly added.
The most interesting story this week is in the ownership register, where flows are moving in opposite directions. FMR (Fidelity) stands out as the most aggressive buyer, adding nearly 4 million shares to reach 7.3 million — a stake worth roughly 7.5% of the company reported through August. BlackRock and State Street also added, with BlackRock lifting its position by 880,000 shares to 5.8 million and State Street adding 486,000. Those are meaningful accumulation signals from large passive and active managers. Running the other direction, L1 Capital trimmed by nearly 3 million shares — the biggest reduction in the register — while Nantahala cut by 2.1 million. The net picture is an institutional base that remains committed at the top but is being quietly thinned by some specialist healthcare funds. One open-market insider buy stands out for context: director Susan Knight purchased 11,000 shares at approximately A$9.29 in early June, a modest but genuine vote of confidence at a price well below current levels.
Short interest is not the story here. At under 1% of the free float — roughly 298,000 shares — the short book is small and has been flat for weeks. The dramatic-looking month-on-month percentage change in the data reflects a step-up from a near-zero base in mid-August rather than any meaningful new bearish position-building. The cost-to-borrow data in the system is stale (last recorded in late January), so borrow conditions cannot be assessed with confidence this week. What can be said is that with short interest this low, squeeze dynamics and borrow pressure are not factors driving price action.
The broader analytical picture is thin but coherent. A single Hold-rated analyst covers the name, and there have been no rating changes in recent weeks. With the company at a pre-profitability stage — negative earnings, negative return on assets, and a price-to-book near 9x — traditional valuation metrics offer little anchor. The EPS surprise factor score ranks in the 84th percentile, meaning AVR has a track record of beating whatever expectations the Street does set. The stock score's momentum pillar is genuinely strong, with the share price sitting well above its long-term moving average despite the recent one-month pullback. Quality and value metrics, by contrast, sit near the bottom of the sector, which explains why the institutional register looks like a mix of high-conviction healthcare specialists and large passive players rather than a broad value-seeking base.
Recent earnings reactions have been mixed but instructive. The September 8 print was met with a 3.4% one-day decline and a further half-percent drift lower over five sessions — modest by biotech standards. The May result triggered a sharper 12% single-day gain and a 35% five-day move, which was the clearest signal that a positive development around the DurAVR transcatheter valve programme can generate outsized price response. The next scheduled event is November 17, giving the stock roughly two months of runway before the market re-prices expectations again.
The key variable between now and November is whether clinical or regulatory news on DurAVR surfaces before the earnings date — the asymmetric earnings reactions in this name suggest the options market, if it were more active here, would price that premium heavily. With borrow data stale and short interest minimal, the next meaningful data point to watch is any shift in the institutional register, particularly whether FMR's August accumulation continues or reverses into the year-end reporting period.
See the live data behind this article on ORTEX.
Open AVR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
